irinotecan has been researched along with tyrosine in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Boyd, G; Burchell, B; Cummings, J; Ethell, BT; Jodrell, DI; Macpherson, JS; Smyth, JF | 1 |
| Ando, M; Hanioka, N; Ishida, S; Jinno, H; Nishimura, T; Ozawa, S; Saeki, M; Saito, Y; Sawada, J; Tanaka-Kagawa, T | 1 |
| Allen, JD; Boyd, G; Cummings, J; Friedberg, TH; Jodrell, DI; Maliepaard, M; Smyth, JF; Yao, D; Zelcer, N | 1 |
| Boyd, G; Burchell, B; Cummings, J; Ethell, BT; Jardine, L; Jodrell, DI; Macpherson, JS; Smyth, JF | 1 |
| Kishida, O; Kiyohara, T; Miyazaki, T; Miyazaki, Y; Murayama, Y; Ogasa, M; Shimomura, I; Shinomura, Y; Tsutsui, S; Watabe, K; Yamamoto, T | 1 |
| Gotwald, T; Hutterer, M; Jacobs, AH; Kostron, H; Muigg, A; Nowosielski, M; Putzer, D; Staffen, W; Stockhammer, G; Tinkhauser, G; Trinka, E; Virgolini, IJ; Waitz, D | 1 |
| Blaum, M; Galldiks, N; Heinzel, A; Langen, KJ; Mottaghy, FM; Müller, D; Verburg, FA | 1 |
| Kjaer, A; Kristoffersen, K; Lassen, U; Madsen, J; Michaelsen, SR; Nedergaard, MK; Poulsen, HS; Stockhausen, MT | 1 |
| Chi, D; He, Z; Lin, X; Liu, H; Sun, J; Wang, Y; Wang, Z; Wu, X; Xu, Z | 1 |
10 other study(ies) available for irinotecan and tyrosine
| Article | Year |
|---|---|
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Topics: Anthraquinones; Camptothecin; Colonic Neoplasms; Enzyme Inhibitors; Glucuronates; Glucuronides; HT29 Cells; Humans; Irinotecan; Magnetic Resonance Spectroscopy; Mass Spectrometry; Metabolic Clearance Rate; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tyrosine | 2002 |
Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D.
Topics: Amino Acid Substitution; Animals; Arginine; Aspartic Acid; Camptothecin; Chlorocebus aethiops; COS Cells; Genetic Variation; Glucuronides; Glucuronosyltransferase; Glutamine; Glycine; Humans; Irinotecan; Proline; Tyrosine | 2003 |
Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.
Topics: Anthraquinones; Antigens, CD; Antineoplastic Agents, Phytogenic; Biological Transport; Camptothecin; Carrier Proteins; Colonic Neoplasms; Drug Interactions; Drug Resistance; Glucuronides; HT29 Cells; Humans; Irinotecan; Membrane Glycoproteins; Membrane Transport Proteins; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Propionates; Quinolines; Tetraspanin 29; Tumor Cells, Cultured; Tyrosine | 2004 |
Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.
Topics: Anthraquinones; Biopsy; Camptothecin; Catalysis; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Enzyme Inhibitors; Food Additives; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Propofol; Topoisomerase I Inhibitors; Tyrosine | 2003 |
Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Amphiregulin; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; EGF Family of Proteins; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Phosphorylation; Quinazolines; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; Transforming Growth Factor alpha; Tyrosine | 2005 |
O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Astrocytoma; Bevacizumab; Brain Neoplasms; Camptothecin; Combined Modality Therapy; Disease-Free Survival; Female; Glioma; Humans; Image Processing, Computer-Assisted; Irinotecan; Magnetic Resonance Imaging; Male; Middle Aged; Nervous System Diseases; Positron-Emission Tomography; Postoperative Complications; Predictive Value of Tests; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Treatment Failure; Tyrosine; Ultrasonography | 2011 |
The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
Topics: Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Camptothecin; Cost-Benefit Analysis; Decision Trees; Disease-Free Survival; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Monte Carlo Method; Neoplasm Grading; Positron-Emission Tomography; Recurrence; Treatment Outcome; Tyrosine | 2013 |
The use of longitudinal 18F-FET MicroPET imaging to evaluate response to irinotecan in orthotopic human glioblastoma multiforme xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Brain; Brain Neoplasms; Camptothecin; Cell Line, Tumor; Female; Glioblastoma; Heterografts; Humans; Irinotecan; Mice, Nude; Neuroimaging; Positron-Emission Tomography; Tyrosine | 2014 |
Tyrosine modified irinotecan-loaded liposomes capable of simultaneously targeting LAT1 and ATB
Topics: Amino Acid Transport Systems; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Humans; Irinotecan; Large Neutral Amino Acid-Transporter 1; Liposomes; Male; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Tyrosine | 2019 |